• Regorafenib: A Mechanism-to-Assay Framework

  2026-09-15

  Regorafenib and BAY 73-4506 offer a powerful way to connect multikinase inhibition with tumor-cell behavior. This evidence-led framework explains how to distinguish direct kinase effects from downstream RRM2 and ERK/E2F3 biology in cancer research.

• Diminazene Aceturate: Research Workflows

  2026-09-15

  Diminazene Aceturate supports two complementary research paths: controlled trypanocidal assays and pathway-focused studies of ACE2-linked cardiac protection. This workflow-centered guide covers stock preparation, assay design, mitochondrial readouts, and troubleshooting without overstating translational evidence.

• NBC19 for Myeloid Inflammasome Assays

  2026-09-14

  NBC19 is an NLRP3 inflammasome inhibitor for separating myeloid-cell phenotype from inflammatory function. This guide translates CAML and polyploid giant-cell findings into rigorous assay decisions while defining the evidence limits of IL-1β release inhibition.

• EZ Cap EGFP mRNA 5-moUTP: Applied Workflows

  2026-09-13

  EZ Cap EGFP mRNA 5-moUTP combines a Cap1 structure, 5-moUTP modification, and an optimized poly(A) tail for reproducible EGFP reporter expression. This article translates those design features into practical workflows for mRNA delivery, translation efficiency testing, fluorescence imaging, and troubleshooting.

• Bestatin hydrochloride: Practical Assay Workflows

  2026-09-12

  Bestatin hydrochloride, also known as Ubenimex, connects aminopeptidase inhibition with practical assays for neuronal signaling, endothelial tube formation, and cancer research. This guide emphasizes experimental controls, dose selection, workflow design, and troubleshooting rather than treating a single phenotype as proof of mechanism.

• Syringin: A Translational Lens on RCC Resistance

  2026-09-12

  Syringin is emerging as a useful research tool for studying renal cell carcinoma resistance, apoptosis, and EGFR/PI3K/Akt signaling. This thought-leadership article examines how recent evidence positions the compound as a candidate sensitizer for sunitinib, while emphasizing botanical-source comparability, assay design, material characterization, and the validation steps required before translational claims are justified.

• Nintedanib (BIBF 1120): Assay Reliability

  2026-09-11

  A scenario-based guide to using Nintedanib (BIBF 1120), SKU A8252, in cell viability, proliferation, and cytotoxicity workflows. It connects receptor pharmacology with practical stock preparation, assay controls, ATRX-aware study design, and evidence-based vendor selection.

• Cy3-UTP for Spatial RNA Biology

  2026-09-11

  Cy3-UTP enables bright, photostable RNA visualization for experiments that connect molecular binding with nuclear organization. This article shows how Cy3-modified uridine triphosphate can support mechanistic assay design inspired by new findings on Alu-containing RNAs and nuclear speckles.

• C34 (CAS 40592-88-9) TLR4 Inhibitor

  2026-09-10

  A practical, scenario-based guide to using C34 (CAS 40592-88-9) TLR4 Inhibitor, SKU B4925, in viability, proliferation, and inflammatory signaling assays. It explains concentration selection, pathway controls, data interpretation, storage, and vendor-quality considerations for reproducible TLR4 research.

• Concanamycin A: V-ATPase Assay Workflows

  2026-09-10

  Concanamycin A provides a fast pharmacological way to test how V-ATPase-dependent acidification shapes lysosomal stress, tumor-cell survival, and invasion. This guide combines practical dosing, glucose-starvation experiments, orthogonal readouts, and troubleshooting for reproducible cancer biology research.

• Nitrocefin: A Smarter β-Lactamase Assay Strategy

  2026-09-09

  Nitrocefin is a chromogenic cephalosporin substrate that converts β-lactamase activity into a visible, measurable signal. This guide connects the Nitrocefin colorimetric assay with GOB-38 research to show how substrate choice, controls, and interpretation improve resistance studies and inhibitor screening.

• VX-745: Rethinking Selective p38α MAPK Inhibition

  2026-09-09

  VX-745 offers translational researchers a selective way to interrogate p38α MAPK biology across inflammation, aging, and cancer models. This thought-leadership analysis connects its biochemical and cellular profile with emerging evidence that kinase conformation can influence phosphatase-driven pathway shutdown, while outlining a practical strategy for rigorous validation.

• Peroxynitrite, ER Ca2+ Flux, and Cardiac I/R Injury

  2026-09-08

  Liu et al. identify an ONOO−-driven ER–mitochondria calcium axis that links hyperhomocysteinemia to cardiac microvascular endothelial necroptosis during ischemia–reperfusion. The study connects IP3R-dependent calcium mis-handling with mitochondrial oxidative injury and shows that IP3R-directed intervention improves cardiac outcomes in hyperhomocysteinemic rats.

• DiD Fluorescence as a Translational Bridge

  2026-09-08

  DiD (DiDC 18 (5)) turns membrane architecture into a measurable translational variable. This thought-leadership analysis connects its mechanistic value in cell tracking and immunofluorescence with the ROS–mitochondrial inflammatory biology of diabetic periodontitis, while defining practical controls, competitive advantages, and boundaries for responsible interpretation.

• Honokiol and Metabolic Context in T-Cell Assays

  2026-09-07

  Honokiol research can be strengthened by separating NF-κB, oxidative-stress, viability, and immunometabolic readouts. This article translates CD8+ T-cell metabolic-flexibility findings into a disciplined assay framework without implying that Honokiol directly regulates the ARS2–PKM axis.

397 records 1/27 page Next 12345 下5页 Last page